The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

September 1, 2021 • By Keri Losavio

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1

You Might Also Like
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database
Explore This Issue
October 2021
Also By This Author
  • Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

Recommendations for healthcare professionals will include consideration of the benefits and risks for individual patients prior to initiating or continuing therapy. In addition, to ensure the benefits of a JAK inhibitor outweigh the risks in patients who receive them, the FDA is limiting all approved uses to certain patients who have not responded to or cannot tolerate one or more tumor necrosis factor (TNF) blockers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Changes will also be made to several sections of the prescribing information and to the patient medication guide.

The Great Debate at ACR Convergence 2020 focused on the question, “Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?” It seems the FDA has now answered that question for rheumatologists.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Basis

Based on a completed review of a large randomized safety clinical trial, the FDA concluded tofacitinib carry an increased risk of serious heart-related events, such as heart attack or stroke, cancer, blood clots and death.1 This trial compared tofacitinib with TNF blockers in patients with rheumatoid arthritis (RA). The trial’s final results also showed an increased risk of blood clots and death with the lower dose of tofacitinib. A prior Drug Safety Communication, based on earlier results from this trial, reported an increased risk of blood clots and death only seen at the higher dose.2

When tofacitinib was first approved, the FDA required the manufacturer, Pfizer, to conduct a randomized safety clinical trial in patients with RA who were taking methotrexate to evaluate the risk of cardiovascular events, malignancy and infections. According to the FDA report, the study was a multi-center, randomized, open-label trial to evaluate two doses of tofacitinib (5 mg twice daily [N=1455], which is the approved dosage for RA, and a higher 10 mg twice daily dosage [N=1456]) in comparison to treatment with a TNF blocker (N=1451).1 Patients in the trial were required to be 50 years of age or older and have at least one cardiovascular risk factor. The co-primary endpoints were major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; and malignancy, excluding nonmelanoma skin cancer (NMSC). The trial was designed to exclude a prespecified risk margin of 1.8 for the hazard ratio of combined tofacitinib regimens when compared with the TNF blocker control for each co-primary endpoint. The median on-study follow-up time was four years.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Safety Tagged With: baricitinib, JAK inhibitors, jakinibs, Tofacitinib, upadacitinibIssue: October 2021

You Might Also Like:
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database
  • FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.